Information for Investors
The opportunity
Pandemic protection
BSAs can be stockpiled in advance to provide a rapid response to emerging viral threats.
Military
BSAs are highly sought after for protection from biowarfare, bioterror, and operational threats.
Acute viral disease
Scores of common viral diseases lack any sort of approved or effective treatment.
Frontline workers
Broad-spectrum antivirals can offer protection to frontline health workers in the early stages of an outbreak.
Broad-spectrum antivirals (BSAs) have many important applications, creating a range of significant markets and opportunities.
Rare diseases
BSAs offer treatment options for rare viral infections lacking specific antiviral therapies.
Cancers
As many as 20% of all cancers are caused by viruses such as HPV, EBV, Hepatitis and Herpes viruses.
Longevity
Chronic viral infections are implicated in immune degradation, multiple cancers and neurological conditions.
Chronic conditions
Latent or persistent viruses cause chronic diseases, such as mononucleosis, shingles and neuralgia.
A Dengue antiviral alone is a $3.8B market
Kimer Med’s lead drug candidate is a first-in-class antiviral for Dengue fever.
Dengue is a Top 10 global health problem that causes immense suffering and kills up to 40,000 people each year (mostly children). Incidence of Dengue is increasing at a higher rate than any other communicable disease and will take off in Europe, USA and Africa this decade, according to the WHO.
There is currently no antiviral for Dengue.
~400M
Dengue cases annually
126M
Clinical cases needing treatment
6.3M
Hospitalisations
(typical cost $3,000)
$3.8B
At NZ$600 per dose,
(one dose per course)
RETURN ON INVESTMENT
First significant revenue projected for 2028, with multiple exit opportunities
-
Our current business model is to out-licence our lead candidate after successful Phase 1 trials. This will provide significant early revenue, plus milestone and royalty payment potential.
-
Various partnerships with large pharmaceutical companies are possible, as well as outright acquisition.
-
An IPO in five to seven years would provide an opportunity for early investors to exit.
Important disclaimer relating to information on this website.
Register your interest for our Series B capital raise.
Important - please read:
DISCLAIMER
The information provided on this website, including any references to future plans or projects, is for general informational purposes only and does not constitute a commitment or guarantee by Kimer Med Limited. While we strive to ensure the accuracy and currency of the content at the time of publication, all information is subject to change without notice. Future plans mentioned may be dependent on external factors, regulatory approvals, or other conditions beyond our control.
Visitors should not rely solely on this information for decision-making and are encouraged to seek independent advice if required. Kimer Med Limited disclaims all liability for any errors, omissions, or inaccuracies in the content and for any actions taken based on this information.